Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 7/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103821 | 0.84 | NOTUM (0.58) | NOTUMRXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL8202120 | 0.79 | NOTUM (0.53) | NOTUMRXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL15057189 | 0.79 | NOTUM (0.53) | NOTUMKDM4EALDH1A1MAPK1KAT6A | |
| SCHEMBL11485495 | 0.79 | KDM4E (0.49) | NOTUMKDM4EALDH1A1MAPK1PDK2 | |
| SCHEMBL8104472 | 0.77 | NOTUM (0.50) | NOTUMKDM4EALDH1A1MAPK1KAT6A | |
| SCHEMBL7027881 | 0.76 | NOTUM (0.49) | NOTUMKDM4EALDH1A1MAPK1KAT6A | |
| SCHEMBL18725354 | 0.76 | NOTUM (0.58) | NOTUMKDM4EALDH1A1MAPK1KAT6A | |
| SCHEMBL3465077 | 0.76 | NOTUM (0.49) | NOTUMRXRAKDM4EALDH1A1MAPK1 | |
| SCHEMBL26921977 | 0.76 | NOTUM (0.58) | NOTUMKDM4EALDH1A1MAPK1PDK2 | |
| SCHEMBL27926581 | 0.76 | NOTUM (0.49) | NOTUMKDM4EALDH1A1MAPK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| CN-114667287-A | Adenosine A2A receptor antagonists and uses thereof | 泰昂治疗公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3999513-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021011670-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011670-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-9604964-B2 | Dihydropyrazole GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2925749-B1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-13 | — | — | US | disclosed |
| EP-2925749-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014078611-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | NOTUM 4731/4885RXRA 234/4885GRIN1 562/4885 |
| US-20160297797-A1 | DIHYDROPYRAZOLE GPR40 MODULATORS | GPR55, GPR65, GPR35 | NOTUM 3629/4885RXRA 881/4885GRIN1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.